Merck’s six-year deal strategy could deliver a blockbuster if hypertension drug is OK’d this month

Kyle LaHucik

Senior Reporter

With an FDA decision expected next week for its blood pressure drug sotatercept, Merck is hoping that its bundle of acquisitions in recent years will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck’s six-year deal strategy could deliver a blockbuster if hypertension drug is OK’d this month

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

FDA updates label of 33-year-old cancer drug with new dose and warning

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Are programs with compounded GLP-1s safe for your population?

Mer­ck’s six-year deal strat­e­gy could de­liv­er a block­buster if hy­per­ten­sion drug is OK’d this month

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Merck’s six-year deal strategy could deliver a blockbuster if hypertension drug is OK’d this month

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

FDA updates label of 33-year-old cancer drug with new dose and warning

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Are programs with compounded GLP-1s safe for your population?